L'Oreal CO ADR (LRLCY)

$72.42 1.76 (2.48%)

12:22 EST LRLCY Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 202.34B

PE Ratio -

EPS -

Volume (Avg. Vol.) 62,024

Day's Range 71.38 - 72.52

52-Week Range 43.46 - 75.92

Dividend & Yield 0.67 (0.93%)

LRLCY Stock Predictions, Articles, and L'Oreal CO ADR News

Here are three solid cosmetic stocks for long-term portfolios. They are likely to have stable growth in the years to come.

Valeant still needs to show it can execute, so now would be the time for those who bought VRX stock at the lows to take some profits.

By Robert Martin, InvestorPlace Writer Jun 26, 2017

Pandora (P) stock jumps on reports of its CEO's departure, GrubHub (GRUB) is downgraded and Nestle (NSRGY) finds itself in Dan Loeb's crosshairs.

Valeant Pharmaceuticals (VRX) finds relief as John Paulson joins the board, but what can he really do to help VRX stock holders?

VRX stock has emerged as one of Thursday's big winners, but it would be wise to crunch the numbers of the deal Valeant Pharmaceuticals just made.

Valeant earnings are due out Tuesday morning, but it would take a laundry list of good news to sustain the rally in VRX stock.

Bill Ackman has abandoned Valeant (VRX), which has almost $30 billion in debt. VRX stock seems to be going through a slow liquidation.

Valeant Pharmaceuticals (VRX) might have a shiny new turnaround plan, but VRX stock is anything but new and improved.

By Ian Bezek, InvestorPlace Contributor Jan 24, 2017

Has Valeant Pharmaceuticals (VRX) turned the corner with its latest asset sales? Or is VRX stock still heading ever closer to zero?

Valeant Pharmaceuticals' (VRX) asset sales could be the start of a breakup. Speculators who get into VRX stock now can still reap rewards.